Abstract
The topical delivery route is proposed as an alternative or adjunctive approach to melanoma treatment, since the target site for melanoma treatment—the epidermal basal layer—is potentially accessible by this route. Microemulsion systems are effective delivery vehicles for enhanced, targeted skin delivery. This work investigated the effect of Rose Bengal (RB) and RB-loaded self-emulsifying microemulsions (SEMEs) on growth inhibition of human melanoma and normal skin cell monolayers, the safety of the excipients incorporated in SEMEs on human cell lines, and the in-vitro human skin penetration of RB delivered in SEMEs and control solution. Cellular toxicity was assessed by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay, and the growth inhibitory mechanism of RB was investigated by flow cytometry using PI staining. Unloaded SEMEs caused reduced cellular toxicity compared to the surfactant excipient, Labrasol®. RB-loaded SEMEs increased cell growth inhibition compared to the RB aqueous solution. Flow cytometry revealed apoptotic cells after treatment with RB-loaded SEMEs, indicating that apoptosis may be one of the mechanisms of cell death. Preliminary results of multiphoton microscopy with fluorescence lifetime imaging (MPM-FLIM) analysis showed deeper penetration with greater skin concentrations of RB delivered from SEMEs compared to the RB aqueous solution. This study highlights the enhanced skin penetration and antimelanoma effects of RB loaded in a SEME system.
Highlights
Cutaneous melanoma is one of the deadliest metastatic neoplastic diseases with an increasing frequency globally
The results showed that the self-emulsifying microemulsions (SEMEs) formulations enhanced antimelanoma potency of Rose Bengal (RB) in all cancerous cell lines, with SEME+propylene glycol (PG) being more potent than SEME formulation without PG (SEME–PG) in reducing cell viability
The WM164 melanoma cell line was the most sensitive, which could be explained by the lack of cell contact inhibition in this cancerous cell type
Summary
Cutaneous melanoma is one of the deadliest metastatic neoplastic diseases with an increasing frequency globally. Topical application of antimelanoma agents might be a useful alternative or adjunctive approach [3,4,5], especially since the target site for melanoma treatment, the epidermal basal layer [6], is potentially accessible by this route. One of the most promising approaches for enhanced topical delivery of agents for the treatment of skin cancer, including melanoma, is the use of nanoencapsulation. In addition to enhancing drug bioavailability by helping to overcome the skin barrier, these nanosystems can enhance stability of the active compound, and aid in the formulation of poorly water-soluble (lipophilic) compounds. They may be further improved by incorporating penetration enhancers [12]
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have